Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS

Lipids in Health and Disease

Julio S Montaner¹  Jayanti Mukherjee⁴  Uchenna H Iloeje⁴  Greg Bondy³  Robert S Hogg²  P Richard Harrigan²  Lawrence McCandless⁵  Adrian R Levy⁵ 

[1] Department of Medicine, UBC, Vancouver, Canada;BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada;St. Paul's Hospital HIV Metabolic and Lipid Clinic, Vancouver, Canada;Bristol-Myers Squibb, Wallingford, Connecticut, USA;Centre for Health Evaluation & Outcome Sciences, St. Paul's Hospital, Vancouver, Canada

关键词: cardiovascular disease;    triglycerides;    cholesterol;    protease inhibitors;    HIV/AIDS;   

Others  :  1213266
DOI  :  10.1186/1476-511X-4-4

 received in 2004-10-01, accepted in 2005-02-10,  发布年份 2005

【 摘 要 】

Background

Protease inhibitors are known to alter the lipid profiles in subjects treated for HIV/AIDS. However, the magnitude of this effect on plasma lipoproteins and lipids has not been adequately quantified.

Objective

To estimate the changes in plasma lipoproteins and triglycerides occurring within 12 months of initiating PI-based antiretroviral therapy among HIV/AIDS afflicted subjects.

Methods

We included all antiretroviral naïve HIV-infected persons treated at St-Paul's Hospital, British Columbia, Canada, who initiated therapy with protease inhibitor antiretroviral (ARV) drugs between August 1996 and January 2002 and who had at least one plasma lipid measurement. Longitudinal associations between medication use and plasma lipids were estimated using mixed effects models that accounted for repeated measures on the same subjects and were adjusted for age, sex, time dependent CD4+ T-cell count, and time dependent cumulative use of non-nucleoside reverse transcriptase inhibitors and adherence. The cumulative number of prescriptions filled for PIs was considered time dependent. We estimated the changes in the 12 months following any initiation of a PI based regimen.

Results

A total of 679 eligible subjects were dispensed nucleoside analogues and PI at the initiation of therapy. Over a median 47 months of follow-up (interquartile range (IQR): 29–62), subjects had a median of 3 (IQR: 1–6) blood lipid measurements. Twelve months after treatment initiation of PI use, there was an estimated 20% (95% confidence interval: 17% – 24%) increase in total cholesterol and 22% (12% – 33%) increase in triglycerides.

Conclusions

Twelve months after treatment initiation with PIs, statistically significant increases in total cholesterol and triglycerides levels were observed in HIV-infected patients under conditions of standard treatment. Our results contribute to the growing body of evidence implicating PIs in the development of blood lipid abnormalities. In conjunction with the predominance or men, high rates of smoking, and aging of the treated HIV-positive population, elevated lipoproteins and triglycerides may mean that patients such as these are at elevated risk for cardiovascular events in the future.

【 授权许可】

   
2005 Levy et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
• [2]Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
• [3]Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
• [4]Thiebaut R, Malvy D, Marimoutou C, Davis F: Anthropometric indices as predictors of survival in AIDS adults. Aquitaine Cohort, France, 1985–1997. Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Eur J Epidemiol 2000, 16:633-639.
• [5]Walli R, Herfort O, Michl GM, et al.: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F173.
• [6]Dube MP, Johnson DL, Currier JS, Leedom JM: Protease inhibitor-associated hyperglycaemia. Lancet 1997, 350:713-714.
• [7]Behrens GM, Stoll M, Schmidt RE: Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 2000, 23:57-76.
• [8]Fantoni M, Del Borgo C, Autore C, Barbaro G: Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents. Ital Heart J 2002, 3:294-299.
• [9]John M, Nolan D, Mallal S: Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001, 6:9-20.
• [10]Vigouroux C, Gharakhanian S, Salhi Y, et al.: Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999, 25:225-232.
• [11]Purnell JQ, Zambon A, Knopp RH, et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14:51-57.
• [12]Hogg RS, O'Shaughnessy MV, Gataric N, et al.: Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997, 349:1294.
• [13]Hogg RS, Yip B, Kully C, et al.: Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999, 160:659-665.
• [14]Allain CC, Poon LS, Chan CS, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem 1974, 20:470-475.
• [15]Naito HK, David JA: Laboratory considerations: determination of cholesterol, triglyceride, phospholipid, and other lipids in blood and tissues. Lab Res Methods Bio Med 1984, 10:1-76.
• [16]Warnick GR, Albers JJ: Heparin – Mn2+ quantitation of high-density-lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 1978, 24:900-904.
• [17]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
• [18]Gonzales G, Estrada M, Ferrer C, Astarioa I, Lahera I: Use of serum cholesterol/triglyceride ratio to discern for which individuals the Friedewald formula can be used confidently. Clin Chem 1990, 36:1673-1675.
• [19]Liang K, Zeger S: Regression analysis for correlated data. Ann Rev Public Health 1993, 14:43-68.
• [20]Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS: The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004, 35:261-268.
• [21]Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS: Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Int Med 2003, 139:810-816.
• [22]Rhew DC, Bernal M, Aguilar D, Iloeje U, Goetz MB: Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin Infec Dis 2003, 37:959-972.
• [23]Martinez E, Arnaiz JA, Podzamczer D, et al.: Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003, 349:1036-1046.
• [24]Fisac C, Virgili N, Ferrer E, et al.: A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab 2003, 88:5186-5192.
• [25]Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
• [26]Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 2001, 285:2486-2497.
• [27]Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Card 1998, 81:7B-12B.
• [28]Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
• [29]Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702-710.
• [30]Friis-Moller N, Sabin CA, Weber R, et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
• [31]Eberly LE, Stamler J, Neaton JD: Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Int Med 2003, 163:1077-1083.
• [32]Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 2000, 11:550-560.
• [33]Turner D, Schapiro JM, Brenner BG, Wainberg MA: The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Antivir Ther 2004, 9:301-314.
• [34]Squires K, Lazzarin A, Gatell JM, et al.: Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV. J Acquir Immune Defic Syndr 2004, 36:1011-1019.
• [35]Wood R, Phanuphak P, Cahn P, et al.: Long-Term Efficacy and Safety of Atazanavir With Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or Atazanavir. J Acquir Immune Defic Syndr 2004, 36:684-692.
• [36]Haas DW, Zala C, Schrader S, et al.: Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003, 17:1339-1349.
• [37]Sanne I, Piliero P, Squires K, Thiry A, Schnittman S: Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003, 32:18-29.
• [38]Murphy RL, Sanne I, Cahn P, et al.: Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003, 17:2603-2614.
• [39]Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
• [40]Clotet B, Negredo E: HIV protease inhibitors and dyslipidemia. AIDS Rev 2003, 5:19-24.
• [41]Penzak SR, Chuck SK: Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovas Drugs 2002, 2:91-106.
• [42]Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48-62.
• [43]Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
• [44]Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
• [45]Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J: Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998, 352:1031-1032.
• [46]Bloomfield RH, Davenport J, Babikian V, et al.: Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001, 103:2828-2833.
• [47]Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585-1591.